-
PF-573228: A Mechanobiology Assay Guide
2026-08-15
PF-573228 is a potent FAK inhibitor for dissecting how focal-adhesion signaling converts substrate stiffness into cell behavior. This guide connects the compound’s pharmacology with dentinogenesis, cancer-cell migration, and endothelial assays while emphasizing controls that prevent mechanistic overinterpretation.
-
FCCP: Mitochondrial Uncoupler for HIF Research
2026-08-14
FCCP, or carbonyl cyanide p-trifluoromethoxyphenylhydrazone, is a lipophilic mitochondrial uncoupler that dissipates the proton gradient supporting ATP synthesis. Its research value spans mitochondrial biology research, oxygen-consumption assays, and inhibition of hypoxia-inducible factor (HIF) pathway studies, but dose responses and downstream phenotypes require model-specific controls.
-
Gepotidacin Mechanism at Staphylococcus aureus Gyrase
2026-08-14
The reference study combines biochemical assays and high-resolution structures to show that gepotidacin inhibits Staphylococcus aureus gyrase through a cleavage pattern distinct from fluoroquinolones. Its selective induction of gyrase-mediated single-stranded DNA breaks, suppression of double-stranded breaks, and structurally defined binding mode provide a mechanistic framework for developing antibacterial agents that can address fluoroquinolone resistance.
-
CSBTA Pharmacokinetics in MASH: Enzyme–Transporter Insights
2026-08-13
The reference study integrates plasma pharmacokinetics, tissue distribution, cellular uptake, metabolism, and transporter regulation to explain why Corydalis saxicola Bunting total alkaloids behave differently in HFHCD-induced MASH mice. Its findings indicate that disease-state changes in CYP450 enzymes, Oatp1b2, P-gp, and PXR-related regulation can increase systemic exposure and hepatic accumulation, informing disease-aware dosing strategies.
-
BV6 and Apoptosis: From IAP Blockade to Assay Insight
2026-08-13
Explore how the IAP antagonist BV6 converts apoptosis biology into a testable perturbation, with practical guidance for interpreting cancer, radiation, and endometriosis models. This article connects BV6 studies with new evidence showing why timing, tissue context, and causal assays matter.
-
Calnexin Shapes CFTR Variant Rescue and Drug Response
2026-08-12
Tedman et al. use deep mutational scanning to show that calnexin-dependent proteostasis influences both CFTR surface expression and corrector responsiveness across 232 clinical variants. The study supports a variant- and cellular-context view of cystic fibrosis research, while cautioning that improved expression does not necessarily predict CFTR-mediated chloride channel activity.
-
Ampicillin Sodium: A Smarter Assay Variable
2026-08-12
Ampicillin sodium is more than a routine selection antibiotic: its concentration, endpoint, and storage history can shape recombinant protein and antibacterial experiments. This article connects β-lactam mechanism, assay interpretation, and the annexin V purification study to build more reproducible workflows.
-
Pentoxifylline Workflows for Inflammation Research
2026-08-11
Pentoxifylline is a practical phosphodiesterase inhibitor for connecting cAMP signaling with cytokine suppression in PBMC, macrophage, infection, and psoriasis workflows. This guide emphasizes assay design, model-specific dosing, controls, and troubleshooting rather than treating one concentration as universally optimal.
-
MK-0812 Workflows for CCR2-Driven MASH Research
2026-08-11
MK-0812 enables controlled interrogation of CCR2-dependent monocyte recruitment in gut–liver inflammation models. Its nanomolar whole-blood activity makes it useful for connecting intestinal TM6SF2 biology, hepatic immune-cell influx, and translational assay development without assuming that CCR2 blockade directly reproduces the study’s LPA intervention.
-
MIZ1–TMBIM4 Control of IgG1+ GC B-Cell Selection
2026-08-10
This preprint identifies an immunoglobulin isotype-specific survival mechanism in germinal-center B cells: MIZ1 supports IgG1+ cell selection by inducing TMBIM4 and controlling BCR-triggered calcium mobilization. The findings connect transcriptional regulation, IP3 receptor signaling, mitochondrial integrity, and positive selection, providing a mechanistic framework for understanding why IgG1+ and IgM+ germinal-center cells do not have identical signaling dependencies.
-
AO/PI Double Staining Kit Protocol Guide
2026-08-09
The AO/PI Double Staining Kit provides a rapid fluorescent cell viability assay that separates viable, apoptotic, and necrotic cell populations using Acridine Orange and Propidium Iodide. It is suitable for screening and routine cell-death assessment, but should not be treated as standalone proof of a specific apoptotic pathway or used for nonfluorescent readouts.
-
DOTAP Workflows for Precision Gene Delivery
2026-08-08
Learn how DOTAP supports reproducible DNA, RNA, and antisense oligonucleotide delivery, from complex formation through transient or stable gene expression. The workflow also shows how to evaluate DOTAP-containing formulations as candidates for localized, mitochondria-focused delivery inspired by a recent glaucoma microneedle study.
-
FK866 (APO866) Workflows for NAD-Targeted Research
2026-08-07
FK866 (APO866) enables controlled interrogation of NAMPT-dependent NAD metabolism, with practical value in AML cytotoxicity studies, metabolic phenotyping, and resistance-model experiments. This workflow-focused guide connects dose-response design, mitochondrial readouts, and the NAD biology of PARP inhibitor resistance while separating established evidence from testable hypotheses.
-
Oltipraz: Optimizing Nrf2 Pathway Activation in MASLD Models
2026-08-07
Oltipraz, a 4-methyl-5-(pyrazin-2-yl)-3H-1,2-dithiole-3-thione, enables robust, reproducible Nrf2 pathway activation and phase II enzyme induction for chemoprevention and metabolic liver disease research. This article synthesizes cutting-edge workflows, troubleshooting, and translational strategies, building on recent breakthroughs in autophagy and ferroptosis modulation.
-
ATRA Sensitizes Ovarian Cancer to PARP Inhibitors Post-Cispl
2026-08-06
This study demonstrates that all-trans retinoic acid (ATRA) can reverse platinum-induced resistance to PARP inhibitors in epithelial ovarian cancer (EOC) models. By downregulating key resistance-associated genes and intracellular NAD+ levels, ATRA enhances the efficacy of PARP inhibition and suggests a promising combinatorial maintenance strategy for EOC.